

To,  
The Corporate Relationship Department  
BSE Limited  
Phiroze Jeejeebhoy Tower  
Dalal Street, Fort  
Mumbai-Maharashtra 400001

Date: 07<sup>th</sup> February, 2026

**Subject: Outcome of Board Meeting held on 07<sup>th</sup> February, 2026 pursuant to regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015**

**Ref: Scrip Code: 526546, ISIN: INE493D01013.**

Dear Sir/Madam,

We wish to inform you that Board of Directors of the Company at their meeting held on **Saturday, 07<sup>th</sup> February, 2026** at the registered office of the Company situated at Survey No 9/1, Near Balaji Tulsiyana Industrial Park, Gram Kumerdi, Indore (M.P.) – 453555 has transacted the following businesses:

1. Considered and approved **Unaudited Financial Results** for the Quarter and Nine Month ended 31<sup>st</sup> December, 2025 along with the Limited review report;
2. Appointment of **Mr. Ritik Pavecha (DIN: 08790431)** as an Additional Director of the Company in the category of the **Non-Executive Independent Director** w.e.f. 07<sup>th</sup> February, 2026 subject to the Conformation of the Members
3. Taken on record the **cessation of directorship of Mrs. Meenaxi Patidar (DIN: 10206356)** due to resignation from the position of Non-Executive Independent Director of the company;
4. Approved postal ballot notice for seeking consent of Members of the Company for the resolutions as set out in the postal ballot Notice and other matters incidental thereto;
5. Approved the appointment of M/s. Surabhi Agrawal, Practicing Company Secretary (COP No. 23696) as Scrutinizer to scrutinize the postal ballot process in a fair and transparent manner.
6. Other routine businesses with the permission of chair.

The meeting of Board of Directors commenced at **12:30 P.M.** and concluded at **02:35 P.M.**

You are requested to please take on record the same.

Thanking You,

Yours faithfully,

**FOR CHOKSI LABORATORIES LIMITED**

**PRAKHAR DUBEY**  
**COMPANY SECRETARY &**  
**COMPLIANCE OFFICER**

*Encl.: Un-audited Financial Results along with limited review report for quarter ended on 31<sup>st</sup> December, 2025*

**CONTINUOUS DISCLOSURE REQUIREMENTS UNDER SUB-PARA 7 OF PARA-A OF PART-A OF SCHEDULE III PURSUANT TO REGULATION 30 OF THE SEBI (LODR) REGULATIONS, 2015**

**The profile and specific areas of expertise of Mr. Ritik Pavecha are as under:**

Reason for change	Appointment of Mr. Ritik Pavecha (DIN: 08790431) as an Additional Director in the category of “Non-Executive Independent Director” of the Company
Date of Birth	18 <sup>th</sup> March, 1994
Date of Appointment & terms of appointment	Appointed on 07 <sup>th</sup> February, 2026 and subject to approval of shareholders
Experience in specific function Area	Mr. Ritik Pavecha is a qualified corporate professional with strong expertise in audit, assurance, corporate compliance, governance, and regulatory advisory. He brings a balanced blend of Big Four audit experience and practicing Company Secretary exposure, enabling him to contribute effectively to Board oversight, risk management, and statutory compliance. He is committed to upholding the highest standards of corporate governance, ethical conduct, transparency, and accountability, making him a suitable candidate for the role of Independent Director.
Disclosure of relationship between Directors (in case of appointment of Director)	He is not related to any KMP/Director and Promoters of company
No. & % of Equity Shares held in the Company	He is not holding any share in the company
Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any order of SEBI/ or any other such authority	We affirm that Mr. Ritik Pavecha is not debarred from holding the office of director by virtue of any order of SEBI/ or any other such authority

**FOR CHOKSI LABORATORIES LIMITED**

**PRAKHAR DUBEY**  
**COMPANY SECRETARY &**  
**COMPLIANCE OFFICER**



# PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS

405, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,

INDORE (M.P.) 452001

PH. 9827013187, 731-3590283

E-MAIL: [teamca@rediffmail.com](mailto:teamca@rediffmail.com)

## Independent Auditor's Review Report on the unaudited Quarterly Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,  
The Board of Directors  
**Choksi Laboratories Limited**  
Indore (M.P.) - 452001

We have reviewed the accompanying statement of unaudited financial results of **CHOKSI LABORATORIES LIMITED** ("the Company") for the quarter ended **December 31, 2025 and year to date results for the period from April, 01, 2025 to December 31, 2025** ("the statement") attached herewith, being submitted by the Company pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE 2410) "Review of Interim Financial Information Performed by Independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



# PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS

405, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,  
INDORE (M.P.) 452001

PH. 9827013187, 731-3590283

E-MAIL: [teamca@rediffmail.com](mailto:teamca@rediffmail.com)



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in all material respect in accordance with the applicable recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR PRATEEK JAIN AND CO.  
CHARTERED ACCOUNTANTS  
FRN-009494C



A handwritten signature in blue ink that reads 'Prateek Jain'.

PRATEEK JAIN  
PROPRIETOR  
M.NO.079214

Date: 7<sup>TH</sup> Feb, 2026

Place: Indore

UDIN: 26079214PUBWWF4585

**CHOKSI LABORATORIES LIMITED**

**Statement of Standalone Unaudited financial Results for the Quarter and Nine Months Ended on 31st December'2025**

(₹ In Lakhs)

As per Schedule III of the Companies Act, 2013

Sl. No.	Particulars	Quarter Ended on			Nine Month Ended on		Year Ended
		3 Months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to Date figures for the current period	Year to Date figures for the corresponding 9 month ended in the previous year	Year to date figures for current period ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
I	<b>Revenue from Operation</b>	1082.47	1111.71	1038.42	3318.37	3038.28	4178.23
II	<b>Other Income</b>	13.34	1.48	0.84	15.15	2.28	6.71
III	<b>Total Income (I+II)</b>	<b>1095.81</b>	<b>1113.19</b>	<b>1039.26</b>	<b>3333.52</b>	<b>3040.56</b>	<b>4184.94</b>
IV	<b>Expenses</b>	88.39	70.90	80.01	243.79	229.73	309.82
	(a) Cost of materials consumed	454.10	457.10	439.01	1370.44	1245.80	1697.66
	(b) Employee benefits expense	80.81	69.36	69.15	210.27	206.78	264.93
	(c) Finance Cost	183.39	168.65	167.75	519.63	479.43	649.88
	(d) Depreciation and amortisation expense	122.89	108.00	115.62	343.69	324.13	408.95
	(e) Laboratories Maintainance Expenses	23.21	25.95	23.64	78.71	76.54	98.77
	(f) Power & Fuel Charges	130.44	156.98	125.84	435.42	388.76	539.60
	(g) Other expenses	1083.23	1056.94	1021.02	3201.95	2951.17	3969.61
	<b>Total expenses</b>	<b>12.58</b>	<b>56.25</b>	<b>18.24</b>	<b>131.57</b>	<b>89.39</b>	<b>215.33</b>
V	<b>Profit / (Loss) before exceptional items and tax (III-IV)</b>	<b>12.58</b>	<b>56.25</b>	<b>18.24</b>	<b>131.57</b>	<b>89.39</b>	<b>215.33</b>
VI	Exceptional items	(77.80)	-	-	(77.80)	-	-
VII	<b>Profit / (Loss) before tax (V-VI)</b>	<b>90.38</b>	<b>56.25</b>	<b>18.24</b>	<b>209.37</b>	<b>89.39</b>	<b>215.33</b>
VIII	<b>Tax Expenses</b>	0.16	14.30	6.87	24.39	20.75	33.38
	(a) Current Tax	-	-	-	-	-	-
	(b) Income Tax Earlier Year	40.82	13.18	7.25	55.88	(6.63)	39.50
	(c) Mat Credit Entitlement	18.36	4.56	(6.46)	35.35	15.07	(9.88)
	(d) Deferred Tax	-	-	-	-	-	-
IX	<b>Net Profit / (Loss) for the period from continuing operations (VII-VIII)</b>	<b>31.04</b>	<b>24.21</b>	<b>10.58</b>	<b>93.75</b>	<b>60.20</b>	<b>152.33</b>
X	<b>Other Comprehensive Income</b>	2.66	36.66	7.61	38.01	24.83	(5.23)
	(a) (i) Items that will not be reclassified to profit & loss	(0.69)	(9.53)	(1.98)	(9.88)	(6.46)	1.36
	(ii) Income tax relating to items that will not be reclassified to profit & loss	0.00	(2.57)	10.05	-	34.11	(15.51)
	(b) (i) Items that will be re-classified to profit & loss	0.00	0.67	(2.61)	-	(8.87)	4.03
	(ii) Income tax relating to items that will be reclassified to profit & loss	33.01	49.44	23.65	121.88	103.81	136.98
XI	<b>Total Comprehensive Income (IX+X)</b>	<b>33.01</b>	<b>49.44</b>	<b>23.65</b>	<b>121.88</b>	<b>103.81</b>	<b>136.98</b>
XII	<b>Detail of equity share capital</b>	696.52	696.52	696.52	696.52	696.52	696.52
	(a) Paid-up equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
	(b) Face value of equity share capital (in Rs.)	-	-	-	-	-	-
XIII	<b>Earnings per equity share (for continuing operations)</b>	0.45	0.35	0.15	1.35	0.86	2.19
	(a) Basic	0.45	0.35	0.15	1.35	0.86	2.19
	(b) Diluted	-	-	-	-	-	-
XIV	<b>Earnings per equity share (for Dis-continuing operations)</b>	-	-	-	-	-	-
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XV	<b>Earnings per equity share (for Dis-continued and continuing operations)</b>	0.45	0.35	0.15	1.35	0.86	2.19
	(a) Basic	0.45	0.35	0.15	1.35	0.86	2.19
	(b) Diluted	-	-	-	-	-	-

Cont..

For Choksi Laboratories Limited

*[Signature]*  
 Managing Director

**Corporate Office & Central Laboratory :**


Survey No. 9/1., Balaji Tulsiyana Industrial Park,  
Kumedi, Off. M.R. 10 Toll Naka, Indore – 453555, M.P. (India)  
Tel. +91 731 3501112 (60 Lines)  
Email : bd@choksilab.com  
Website : www.choksilab.in

**Notes to the results :**

- 1 These results have been prepared as per Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 and in accordance with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules 2015 as amended and other accounting principles generally accepted in India.
- 2 The figures for the quarter ended on 31st December, 2025 are the balancing figures between unaudited figures in respect of the Quarter ended on December 31, 2025 and the published unaudited figures for the quarter and Half Year ended on September 30, 2025.
- 3 The above Financial Results for the quarter ended on 31st December 2025 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Saturday, 07th February 2026.
- 4 Depreciation on fixed assets is provided on straight line method as per the estimated remaining useful lives of assets.
- 5 The Company has identified "Analysis and Testing" as the single operating segment for the continued operations in the financial statements as per Ind AS 108 "Operating Segments".
- 6 Revenue from Operations is shown exclusive of GST
- 7 "Other Income" for the quarter and nine months ended on 31st December 2025 includes :-  
Interest Income ₹ 0.58, Interest on IT Refund ₹ 13.26 Lakhs Cash Back on Credit Card ₹ 0.21 Lakhs, & Forex Gain ₹ 1.10 Lakhs.
- 8 Exceptional Item: During the quarter, the Company sold an office flat resulting in a gain of ₹77.80 Lakhs. The transaction is non-recurring in nature and does not form part of the Company's ordinary operating activities. Accordingly, the gain has been disclosed as an Exceptional Item in the Statement of Profit and Loss.
- 9 Figures for the previous periods have been regrouped, wherever necessary and minus figures are shown in brackets.
- 10 Earnings per share amount is shown in Rupees (₹).
- 11 For any queries email at compliance\_officer@choksilab.in

Date: 07<sup>th</sup> February 2026  
Place: Indore

For and on behalf of the Board of Directors of  
CHOKSI LABORATORIES LIMITED

  
Sunil Choksi  
Managing Director  
DIN 00155078

